ECM
HZNP

Endurant Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Endurant Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,454
Closed -$674K – 73
2022
Q2 		$674K Buy
+8,454
New +$801K 0.26% 43
2016
Q4 		– Sell
-26,040
Closed -$472K – 102
2016
Q3 		$472K Sell
26,040
-30,400
-54% -$594K 0.17% 75
2016
Q2 		$930K Sell
56,440
-42,400
-43% -$686K 0.31% 56
2016
Q1 		$1.64M Buy
98,840
+42,900
+77% +$751K 0.53% 48
2015
Q4 		$1.21M Sell
55,940
-64,760
-54% -$1.26M 0.41% 54
2015
Q3 		$2.39M Buy
+120,700
New +$3.81M 0.8% 41
2015
Q2 		– Sell
-29,700
Closed -$771K – 112
2015
Q1 		$771K Buy
+29,700
New +$544K 0.25% 76

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return